MetaCap

Phio Pharmaceuticals (PHIO) vs Rocket One (RKTO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Phio Pharmaceuticals (PHIO) has outperformed Rocket One (RKTO) over the past year, losing 41.4% versus a loss of 72.6%. Over five years, RKTO leads with a -98.6% price change compared with -99.6% for PHIO. Phio Pharmaceuticals is the larger company by market cap ($7.8 million vs $7.4 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PHIO-41.43%RKTO-72.63%
+114%+15%-83%
Nov 21, 20251 yearNov 20, 2026
PHIO-99.56%RKTO-98.59%
+80%-14%-108%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PHIO versus RKTO key metrics
MetricPHIORKTO
Share price$0.656$0.297
Market cap$7.84M$7.39M
1-day change-8.25%+5.24%
YTD return-37.52%-70.00%
1-year return-41.43%-72.63%
5-year return-99.56%-98.60%
EPS (TTM)$-1.21$-0.82
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-8.70M$-12.47M
52-week high$1.88$2.45
52-week low$0.6395$0.26
Distance from 52-week high-65.11%-87.88%
Analyst consensusnone—
Avg. price target upside+2034.15%—
Average volume106.09K338.12K
Shares outstanding11.95M24.90M
Employees62
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PHIO has outperformed RKTO by 31.2 percentage points over the past year.

About Phio Pharmaceuticals

PHIO stock →

Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies.

Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees

About Rocket One

RKTO stock →

Rocket One Inc. focuses on developing and commercializing AI semiconductor infrastructure.

Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees

PHIO vs RKTO FAQ

Which is bigger, Phio Pharmaceuticals or Rocket One?

Phio Pharmaceuticals (PHIO) is larger, with a market capitalization of $7.84M compared with $7.39M for Rocket One (RKTO).

Which stock has performed better over the past year, PHIO or RKTO?

PHIO returned -41.43% over the past 12 months, compared with -72.63% for RKTO (price return, excluding dividends). Past performance does not predict future results.

Are Phio Pharmaceuticals and Rocket One in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons